FMC Corporation (FMC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals several concerning factors: a decline in adjusted EBITDA and EPS, reduced free cash flow guidance, and a significant dividend cut. The Q&A session highlights uncertainties, such as potential company sale and unclear management responses. Although there are plans for cost reduction and a new product pipeline, the immediate financial outlook is weak, with competitive pricing pressures and declining sales in key areas. These factors, combined with the strategic review and potential sale, suggest a negative sentiment and likely stock price decline.
Key Financial Performance
Q4 2025 Sales $1.08 billion, a decline of 11% year-over-year or 5% on a like-for-like basis, excluding India. Reasons: Price declined 6% due to lower Rynaxypyr and strong market competition, particularly in Latin America. Volumes declined 1% due to high competitive pressure.
Q4 2025 Adjusted EBITDA $280 million, a decline of 17% year-over-year, down 8% on a like-for-like basis, excluding India. Reasons: Lower price and volume were partially offset by lower costs and FX.
Q4 2025 Adjusted EPS $1.20, a 33% decline year-over-year. Reasons: Lower adjusted EBITDA and higher interest.
2025 Sales of Core Products (excluding Rynaxypyr) Approximately $2.2 billion. Nearly $1 billion of these sales came from products manufactured in high-cost facilities. Reasons: High manufacturing costs and competition.
2025 Sales of Rynaxypyr Just over $800 million, in line with expectations. Reasons: Post-patent strategy and market dynamics.
2025 Sales of New Active Ingredients Increased from approximately $130 million in 2024 to approximately $200 million in 2025, a 54% growth. Reasons: Driven by fluindypyr and Isoflex, though below expectations due to later-than-expected registration for Isoflex in Great Britain.
2025 Free Cash Flow Negative $165 million. Reasons: Included $103 million of cash restructuring spending.
2025 Net Debt Approximately $3.5 billion, down over $550 million from the third quarter. Reasons: Strong free cash flow in Q4.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Active Ingredients: Sales increased from $130 million in 2024 to $200 million in 2025, driven by fluindypyr and Isoflex. Sales of new active ingredients are expected to grow to $300-$400 million in 2026 and exceed $2 billion by 2035.
Rynaxypyr Post-Patent Strategy: 2025 sales were $800 million. Generic offerings will be available in 2026, and the company plans to lower prices and grow volume. Branded Rynaxypyr earnings are expected to remain stable in 2026.
India Commercial Business Sale: The sale process is progressing, with binding bids expected in Q2 2026. This is part of a broader strategy to pay down over $1 billion in debt.
Debt Reduction: Targeting over $1 billion debt reduction through asset sales and licensing agreements.
Cost Reduction in Core Portfolio: Plans to lower manufacturing costs of non-diamide products by 35% by 2027. This involves re-registration and inventory buildup, which may act as a sales headwind in 2026.
Strategic Review: The Board is exploring strategic options, including a potential sale of the company, to maximize shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Debt Reduction and Asset Sales: The company plans to pay down over $1 billion of debt through asset sales and licensing agreements, including the sale of its India commercial business. However, this strategy is dependent on successful execution, and any delays or failures in asset sales or licensing agreements could adversely impact financial stability.
Manufacturing Cost Reduction: Efforts to lower manufacturing costs of non-diamide products by 35% by 2027 require re-registration of products and inventory buildup. This process limits flexibility to adapt to customer needs, creating a sales headwind in 2026.
Post-Patent Strategy for Rynaxypyr: Generic offerings of CTPR in all markets starting in 2026 are expected to increase pest resistance and intensify competition. This could impact sales and market share, despite efforts to lower prices and grow volume.
New Active Ingredients Sales: Sales of new active ingredients were below expectations in 2025 due to delayed registrations. While growth is anticipated, any further delays or regulatory hurdles could hinder revenue targets.
Tariff Impacts: Tariffs are expected to create a $20 million headwind, primarily affecting first-quarter results in 2026.
Competitive Pressures: Intense competition from generics and weaker grower margins have already impacted sales and pricing, particularly in Latin America. This trend is expected to continue, posing risks to revenue and profitability.
Free Cash Flow Challenges: 2026 free cash flow is projected to range from negative $65 million to positive $65 million, indicating potential liquidity challenges. This is compounded by lower EBITDA and higher restructuring costs.
Regulatory and Registration Risks: Planned registration losses in Europe and delays in product registrations, such as Isoflex in Great Britain, could negatively impact sales and market expansion.
Economic and Market Conditions: Weaker grower margins and high competitive pressure have already affected product mix and timing of purchases, creating uncertainties in revenue generation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Debt Reduction: Targeting paying down over $1 billion of debt through asset sales and licensing agreements, including the sale of the India commercial business.
Manufacturing Cost Reduction: Plan to lower the manufacturing cost of non-diamide products by at least 35% by 2027, despite expected sales headwinds in 2026 due to reduced flexibility.
Rynaxypyr Post-Patent Strategy: Anticipate branded Rynaxypyr earnings in 2026 to be in line with prior year, with higher volume and lower costs offsetting lower prices. Generic offerings of CTPR expected in all markets starting 2026.
New Active Ingredients Sales Growth: Estimate 2026 sales for new active ingredients to be between $300 million and $400 million, with expectations to exceed $2 billion by 2035.
2026 Full Year Guidance: Expecting full year sales of $3.6 billion to $3.8 billion, down 5% at the midpoint versus prior year. Adjusted EBITDA expected to be between $670 million to $730 million.
First Quarter 2026 Guidance: Sales guidance of $725 million to $775 million, 5% lower than prior year. Adjusted EBITDA expected to be between $45 million and $50 million, representing a 58% decline year-over-year.
Free Cash Flow Outlook for 2026: Expected to range from negative $65 million to positive $65 million, with breakeven at the midpoint. Includes $130 million in restructuring spending.
Long-Term Growth Projections: EBITDA growth expected in the mid-teens percent in both 2027 and 2028, driven by new active ingredients and improved competitiveness of the core portfolio.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the relative contributions to the $700 million EBITDA target for this year from different product groups?
A:Management does not break out profitability by product line. However, the core portfolio (non-Rynaxypyr) is a significant contributor, making up about half of the company's sales. Branded Rynaxypyr earnings are expected to remain flat year-on-year, while partner sales of Rynaxypyr are expected to decline due to lower prices and volumes. The growth portfolio, including Cyazypyr, new active ingredients, and Plant Health, is expected to contribute increasing profitability.
Q:How does management plan to achieve mid-teens EBITDA growth in 2027 and 2028?
A:Management plans to achieve this growth through continued performance of the growth portfolio, which has been stable over the past two years, and by addressing challenges in the core portfolio. They are restructuring their manufacturing footprint to improve cost competitiveness and expect the impact of Rynaxypyr partner contracts to diminish as the size of these contracts becomes smaller.
Q:Has there been any discussion or interest in the sale of the entire company?
A:Management has initiated a process to explore the sale of the entire company as one of two parallel paths. This decision was made after discussions with the Board to explore ways to increase shareholder returns and potentially improve the company's performance under different ownership. Advisors have been hired, and the process is being structured.
Q:What is the thought process behind initiating a strategic review and weighing a full sale versus other options?
A:The company is pursuing two separate paths: the base plan, which includes debt reduction and improving competitiveness, and a potential full sale of the company. The full sale is being considered to potentially enhance shareholder returns and allow the company to operate more effectively under different ownership. Partial divestitures, such as asset sales and licensing agreements, are part of the base plan.
Q:Is it possible to sell parts of the company, such as the new molecules or diamides, separately?
A:While the company is set up in a way that could allow for multiple options, management is currently focusing on two main paths: the base plan (including licensing and asset sales) and a full sale of the company. They are open to other ideas if they arise but are not actively pursuing them.
Q:What is the revenue outlook for different product buckets in 2026 compared to 2025?
A:Branded Rynaxypyr earnings are expected to remain flat, with slight revenue declines. Partner sales of Rynaxypyr are expected to shrink due to lower prices and volumes. The legacy core portfolio is expected to contract slightly year-on-year due to pricing and volume pressures. The growth portfolio, including new active ingredients, Cyazypyr, and Plant Health, is expected to grow, with the strongest growth coming from new active ingredients.
Q:How confident is management in addressing the company's challenges and achieving a turnaround?
A:Management is confident in their ability to address challenges, particularly in the core portfolio outside of Rynaxypyr, which has been impacted by generics and cost competitiveness issues. They are restructuring their manufacturing footprint and believe the rest of the portfolio is performing as expected. They acknowledge past missteps but have a clear plan to fix the core portfolio.
Q:Why is the company considering a sale at what appears to be the bottom of the cycle?
A:Management believes the base plan will lead to growth starting in 2027, but the Board is exploring a sale to potentially enhance shareholder returns and allow the company to operate more effectively under different ownership. They are pursuing both paths in parallel to ensure the best outcome for shareholders.
Q:What is the plan for upcoming debt maturities and covenant obligations?
A:The company plans to refinance $500 million in bonds maturing in October, with discussions underway to determine the best financing options. They aim to reduce total debt by $1 billion through asset sales, licensing agreements, and other measures. They have renegotiated their revolving credit facility to allow for higher covenants and are focused on managing cash flows to stay within these limits.
Q:Why did new product revenue fall short of expectations, and what factors could influence future revenue?
A:The $50 million shortfall in new product revenue was primarily due to a registration delay for Isoflex and lower-than-expected direct sales in Brazil, including fluindypyr. Future revenue will depend on the speed of registrations and market penetration, particularly for Isoflex.
Q:What is the outlook for Rynaxypyr, including partner sales and branded sales?
A:Partner sales of Rynaxypyr are expected to decline due to lower prices and volumes. Branded Rynaxypyr earnings are expected to remain flat, supported by a shift to advanced formulations, which command higher prices. Management is confident in maintaining profitability through cost reductions and volume growth in advanced formulations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific profitability breakdowns by product line, citing that they do not disclose such details. Additionally, they did not provide precise numbers for the impact of Rynaxypyr partner sales on EBITDA, instead offering only directional guidance. They also used vague language when discussing the potential benefits of a full sale versus the base plan, without detailing how these would be quantified or achieved.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America pricing
Brazil patent
Britain sale
CEO Non
CTPR chlorantraniliprole
CTPR generic
Chairman night
Directors
India headwind
Isoflex
Non Chairman
President CEO
Price digit
active
basis India
capital cash
competition
competitiveness
condition
core portfolio
cost product
decline basis
example
flow debt
formulation mixture
licensing agreement
margin
offering
option
portfolio product
price volume
priority balance
removal India
resistance
restructuring spending
sale ingredient
sale line
stage
success
FMC Transcript
FMC Corporation (FMC) Q4 2025 Earnings Call Transcript
Unknown2-5
The earnings call summary reveals several concerning factors: a decline in adjusted EBITDA and EPS, reduced free cash flow guidance, and a significant dividend cut. The Q&A session highlights uncertainties, such as potential company sale and unclear management responses. Although there are plans for cost reduction and a new product pipeline, the immediate financial outlook is weak, with competitive pricing pressures and declining sales in key areas. These factors, combined with the strategic review and potential sale, suggest a negative sentiment and likely stock price decline.
FMC Corporation (FMC) Presents at Goldman Sachs Industrials and Materials Conference 2025 Transcript
Neutral12-3
FMC Corporation (FMC) Q3 2025 Earnings Call Transcript
Unknown10-30
The earnings call presents mixed signals. Financial performance and guidance are stable, but with weak revenue guidance and flat EPS. Product development shows promise with new launches, but competitive and tariff pressures remain. The India divestment and debt reduction are positives, but uncertainties in receivables and market challenges persist. Shareholder returns are not a focus currently. Overall, the sentiment is balanced, leading to a neutral prediction.
FMC Corporation (FMC) Corporation Presents At Jefferies Mining And Industrials Conference 2025 Transcript
Neutral9-3
FMC Slides
FMC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
